nach oben

Der Nervenarzt

Erschienen in:

01.01.2008 | Übersichten

Behandlung der Demenz bei Parkinson-Syndromen

Wirksamkeit von Cholinesterasehemmern

verfasst von: I. Liepelt, W. Maetzler, H.-P. Blaicher, T. Gasser, D. Berg

Erschienen in: Der Nervenarzt | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Demenz ist eine häufige Begleiterscheinung bei verschiedenen Parkinson-Syndromen. Eine Verringerung an Acetylcholin, d. h. eine Störung im cholinergen Neurotransmittersystem, wird als Ursache der kognitiven Leistungsbeeinträchtigung diskutiert. Studien weisen darauf hin, dass eine Behandlung mit Cholinesterasehemmern (ChEIs) eine mögliche Therapieoption zur Behandlung der Demenz bei Parkinson-Erkrankungen bietet. Nachfolgend werden die Hauptmerkmale der Demenz bei Morbus Parkinson (PDD), der Demenz mit Lewy-Körperchen (DLK), der Demenz bei progressiver supranukleärer Blickparese (PSP) und bei kortikobasaler Degeneration (CBD) dargestellt und der Behandlungseffekt mit ChEIs bei diesen Erkrankungen kritisch hinterfragt. Zusammenfassend besteht Evidenz, dass die Gabe einiger ChEIs bei PDD die kognitiven Fähigkeiten und, in einem geringeren Ausmaß, die Alltagskompetenz verbessern. Ebenso wirken sie positiv auf das Verhalten bei PDD und DLK. Für Aussagen zur Wirksamkeit der ChEIs bei PSP und CBD sind noch weitere Studien mit höheren Patientenzahlen, längeren Untersuchungszeiträumen und geeigneten Testverfahren notwendig.

Aarsland D, Andersen K, Larsen JP et al. (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56: 730–736PubMed

Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18: 937–941PubMedCrossRef

Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72: 708–712PubMedCrossRef

Aarsland D, Perry R, Brown A et al. (2005) Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 58: 773–776PubMedCrossRef

Albert ML, Feldman RG, Willis AL (1974) The ‚subcortical dementia‘ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121–130PubMed

Ballard C, Piggott M, Johnson M et al. (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 48: 868–876PubMedCrossRef

Beversdorf DQ, Warner JL, Davis RA et al. (2004) Donepezil in the treatment of dementia with lewy bodies. Am J Geriatr Psychiatry 12: 542–544PubMedCrossRef

Birks J, Grimley EJ, Iakovidou V, Tsolaki M (2000) Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 4: CD001191PubMed

Birks JS, Melzer D, Beppu, H (2000) Donepezil for mild and moderate Alzheimer’s disease. Cochrane Database Syst Rev 4: CD001190PubMed

10.

Blin J, Mazetti P, Mazoyer B et al. (1995) Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 118: 1485–1495PubMedCrossRef

11.

Bohnen NI, Kaufer DI, Hendrickson R et al. (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253: 242–247PubMedCrossRef

12.

Bohnen NI, Kaufer DI, Ivanco LS et al. (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60: 1745–1748PubMedCrossRef

13.

Braak H, Rub U, Jansen Steur EN et al. (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64: 1404–1410PubMed

14.

Cordato NJ, Pantelis C, Halliday GM et al. (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125: 789–800PubMedCrossRef

15.

Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2: 229–237PubMedCrossRef

16.

Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351: 2509–2518PubMedCrossRef

17.

Fabbrini G, Barbanti P, Bonifati V et al. (2001) Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 103: 123–125PubMedCrossRef

18.

Frattali CM, Grafman J, Patronas N et al. (2000) Language disturbances in corticobasal degeneration. Neurology 54: 990–992PubMed

19.

Giladi N, Shabtai H, Gurevich T et al. (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 108: 368–373PubMedCrossRef

20.

Gilman S, Koeppe RA, Little R et al. (2005) Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol [Suppl 1] 191: S95–S103

21.

Grace J, Daniel S, Stevens T et al. (2001) Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 13: 199–205PubMedCrossRef

22.

Grace JB, Walker MP, McKeith IG (2000) A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 15: 1028–1033PubMedCrossRef

23.

Graham NL, Bak TH, Hodges JR (2003) Corticobasal degeneration as a cognitive disorder. Mov Disord 18: 1224–1232PubMedCrossRef

24.

Groschel K, Hauser TK, Luft A et al. (2004) Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 21: 714–724PubMedCrossRef

25.

Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102: 355–363

26.

Higginson CI, King DS, Levine D et al. (2003) The relationship between executive function and verbal memory in Parkinson’s disease. Brain Cogn 52: 343–352PubMedCrossRef

27.

Hilker R, Thomas AV, Klein JC et al. (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716–1722PubMedCrossRef

28.

Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 61: 324–325PubMedCrossRef

29.

Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 18: 149–154PubMedCrossRef

30.

Jellinger K, Danielczyk W, Fischer P, Gabriel E (1990) Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 95: 239–258PubMedCrossRef

31.

Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson’s disease. J Neurol Sci 248(1–2): 167–172

32.

Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (Berl) 112(3): 253–260

33.

Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109: 329–339PubMedCrossRef

34.

Kertzman C, Robinson DL, Litvan I (1990) Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47: 1346–1350PubMed

35.

Kompoliti K, Goetz CG, Boeve BF et al. (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55: 957–961PubMedCrossRef

36.

Le Rhun E, Richard F, Pasquier F (2005) Natural history of primary progressive aphasia. Neurology 65: 887–891CrossRef

37.

Leroi I, Brandt J, Reich SG et al. (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 19: 1–8PubMedCrossRef

38.

Litvan I, Cummings JL, Mega M (1998) Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 65: 717–721PubMed

39.

Litvan I, Gomez C, Atack JR et al. (1989) Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26: 404–407PubMedCrossRef

40.

Litvan I, Phipps M, Pharr VL et al. (2001) Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57: 467–473PubMed

41.

Loy C, Schneider L (2004) Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 4: CD001747PubMed

42.

Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 4: CD001747

43.

McKeith I, Del Ser T, Spano P et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031–2036PubMedCrossRef

44.

McKeith IG (2002) Dementia with Lewy bodies. Br J Psychiatry 180: 144–147PubMedCrossRef

45.

McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65: 1863–1872PubMedCrossRef

46.

McKeith IG, Grace JB, Walker Z et al. (2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15: 387–392PubMedCrossRef

47.

Minett TS, Thomas A, Wilkinson LM et al. (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18: 988–993PubMedCrossRef

48.

Miyasaki JM, Shannon K, Voon V et al. (2006) Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (Published online)

49.

Papapetropoulos S, Gonzalez J, Mash DC (2005) Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 54: 1–9PubMedCrossRef

50.

Pillon B, Czernecki V, Dubois B (2003) Dopamine and cognitive function. Curr Opin Neurol [Suppl 2] 16: 17–22

51.

Poewe W, Wolters E, Emre M et al. (2005) Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: An active treatment extension study. Mov Disord 21(4): 456–461CrossRef

52.

Putt ME, Ravina B (2002) Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson’s disease. Control Clin Trials 23: 111–126PubMedCrossRef

53.

Querfurth HW, Allam GJ, Geffroy MA et al. (2000) Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 11: 314–321PubMedCrossRef

54.

Quinn NP (2005) How to diagnose multiple system atrophy. Mov Disord [Suppl 12] 20: S5–S10

55.

Ravina B, Putt M, Siderowf A et al. (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76: 934–939PubMedCrossRef

56.

Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171–1174PubMedCrossRef

57.

Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794–802PubMedCrossRef

58.

Schneider JA, Watts RL, Gearing M et al. (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48: 959–969PubMed

59.

Shinotoh H, Namba H, Yamaguchi M et al. (2001) In vivo mapping of brain cholinergic function in Parkinson’s disease and progressive supranuclear palsy. Adv Neurol 86: 249–255PubMed

60.

Tiraboschi P, Hansen LA, Alford M et al. (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407–411PubMed

61.

Warren NM, Piggott MA, Perry EK, Burn DJ (2005) Cholinergic systems in progressive supranuclear palsy. Brain 128: 239–249PubMedCrossRef

62.

Watts RL, Mirra SS, Richardson EP Jr (eds) (1994) Corticobasal ganglionic degeneration. Vol. 3, Butterworth-Heinemann, Oxford, pp 282–299

63.

Werber EA, Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm 108: 1319–1325PubMedCrossRef

64.

Wesnes KA, McKeith I, Edgar C et al. (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65: 1654–1656PubMedCrossRef

65.

Wesnes KA, McKeith IG, Ferrara R et al. (2002) Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13: 183–192PubMedCrossRef

66.

Wild R, Pettit T, Burns A (2003) Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 3: CD003672PubMed

67.

Zgaljardic DJ, Foldi NS, Borod JC (2004) Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm 111: 1287–1301PubMedCrossRef

68.

Thomas AJ, Burn DJ, Rowan EN et al. (2005) A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20: 938–944PubMedCrossRef

69.

Edwards KR, Hershey L, Wray L et al. (2004) Efficacy and safty of galantamine in patients with dementia with Lewy bodies: a 12 week interim analysis. Dement Geriatr Cog Disord 17 [Suppl 1]: 40–48

Titel: Behandlung der Demenz bei Parkinson-Syndromen
Wirksamkeit von Cholinesterasehemmern
verfasst von: I. Liepelt
W. Maetzler
H.-P. Blaicher
T. Gasser
D. Berg
Publikationsdatum: 01.01.2008
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 1/2008
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-007-2312-2

Springer Medizin

Behandlung der Demenz bei Parkinson-Syndromen

Wirksamkeit von Cholinesterasehemmern

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

Schützt Olivenöl vor dem Tod durch Demenz?

Darf man die Behandlung eines Neonazis ablehnen?

Chirurginnen und Chirurgen sind stark suizidgefährdet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Psychische Störung und Aussagetüchtigkeit

Nikotin und Gehirnentwicklung

Pharmakotherapie bei Schizophrenie und komorbider Substanzstörung

Psychotische Syndrome bei kriegstraumatisierten älteren Patienten

Längsschnittuntersuchung alkoholauffälliger Mitarbeiter in einem Großbetrieb nach werksärztlicher Kurzintervention

Neues vom DGBS Arbeitskreis Junge Wissenschaftler

Neu in den Fachgebieten Neurologie und Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

Schützt Olivenöl vor dem Tod durch Demenz?

Darf man die Behandlung eines Neonazis ablehnen?

Chirurginnen und Chirurgen sind stark suizidgefährdet